Pain Therapeutics, Inc. (NASDAQ:PTIE)

CAPS Rating: 3 out of 5

A biopharmaceutical company that develops novel drugs for pain management and oncology.


Player Avatar Simbalion200 (24.04) Submitted: 4/9/2010 10:54:24 AM : Outperform Start Price: $3.70 PTIE Score: -117.77

Pain Therapeutics, Inc. is a biopharmaceutical company that develops drugs. As of December 31, 2009, the Company had four drug candidates in clinical programs, including REMOXY, PTI-202, PTI-721 and a radio-labeled monoclonal antibody to treat metastatic melanoma. The Company's lead drug candidate is REMOXY, which is a painkiller. It has a collaboration agreement and a license agreement with King Pharmaceuticals, Inc. (King) to develop and commercialize REMOXY and other opioid painkillers. I am not excited about this company. Right now the company is not profitable. One year EPS growth is encouraging at 412.50%. The Return on Equity is a pitiful -3.23. The positive consideration is that there is always interest in effective pain medicines. Stock has been on a steady upward progression over the last year. However, this stock may be overbought, and I expect the stock price will begin to decline in price a bit. I do believe after a short correction this stock will outperform the market.

Featured Broker Partners